U.S. Patent and Trademark Office, Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless:

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09651294	
Filing Date		2000-08-30	
First Named Inventor	Taku	ma Kobayashi	
Art Unit		2154	
Examiner Name	A. Patel		
Attorney Docket Number		00862.021995.	

					U.S.	PATENTS			Remove		
Examiner Cite Initial* Patent Number Kind Code1 Issue		Issue C	ate	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear					
	1	5379237		1995-0	1-03	Morgan et al					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	_	Add		
	U.S.PATENT APPLICATION PUBLICATIONS Remove										
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee or Applicant of cited Document		Releva		Lines where ges or Relev	
	1										
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Ad	d button	Add		
				FOREIG	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date Name of Patente Applicant of cited Document		e or	where Rel	or Relevant	ть
	1	06-168145	JP			1994-06-14	Shimizu et al				
	2	02-280235	JP			1990-11-16	Nozawa et al				
	3	04-033105	JP			1992-02-04	Takahaski				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

plication Number		09651294		
ing Date		2000-08-30		
rst Named Inventor	Taku	ma Kobayashi		
t Unit		2154		
aminer Name	A. Pa	stel		
torney Docket Numb	or	00862 021995		

4 05-502391 JP 1993-04-22 Morgan et al. 5 91/19164 WO 1991-12-12 Morgan et al.								
5 91/19164 WO 1991-12-12 Morgan et al.								
If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials* No (blook, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and country where published.								
1								
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

A

E

See Kink Codes of USPTO Platent Documents at year, <u>USPTO,000</u> or MPEP D0.04. * Enter office in all issued the document, by the two-letter code (WPD-Standard ST3.). * *Plate pagence painted connects, the indication of the pagent of the integer of the integer of the integer code the senial number of the pagent document of the document by the appropriate symbols as indicated on the document unfor WPD Standard ST.16 if possible. * *Applicant is to place a check mark here if complete integer pagent pagency and the pagency an

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09651294
Filing Date		2000-08-30
First Named Inventor Takur		ma Kobayashi
Art Unit		2154
Examiner Name	A. Pa	Ael
Attorney Docket Number		00862.021995.

42 746

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication [7] from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to let not information contained in the information disclosure statement was known to any individual designated in 37 CFR 13/60; more than three months prior to the filing of the information disclosure statement Sec. 37 CFR 13/60; more than three months prior to the filing of the information disclosure statement Sec. 37 CFR 13/60; more than three months prior to the filing of the information disclosure statement Sec. 37 CFR 13/60; more than three months prior to the filing of the information disclosure statement Sec.

- ☐ See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Edward A Kmett

□ None

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

norm or the signature.			
Signature	/Edward Kmett/	Date (YYYY-MM-DD)	2006-09-21

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 3 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Comments of C

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is \$5 U.S. C. 2(b)(2); (2) furnishing of the information solicide that.) (1) the general authority for the collection of this information is used by the U.S. Patient and Trademan Koffice is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested in the contraction of the contraction of the patient o

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, during an inspection of records conducted by GSA a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S. C. 294 and 2906. Such Adeckouse shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the againston pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record vals filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application pare to public insepections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.